期刊文献+

食管胃交界部肿瘤的最新研究进展 被引量:3

Recent advances in carcinoma of the esophagogastric junction
暂未订购
导出
摘要 近年来,食管胃交界部肿瘤(carcinoma of esophagogastric junction,CEG)发病率明显升高,但是在其分类、病因、治疗原则等很多方面存在争议,争议源于贲门解剖学位置和结构的复杂性。目前学术界普遍采用的是Siewert分类法,将肿瘤分为三类:AEG I型、AEG II型和AEG III型。胃食管返流性疾病、食管裂孔疝、幽门螺旋杆菌、饮食、生活习惯和药物等都是导致CEG肿瘤发生重要因素,这些因素导致上皮细胞在基因和染色体水平出现紊乱,最终促使正常细胞演变为肿瘤细胞,但是具体的机制还有待深入研究和探讨。本文对上述问题的最新研究进展进行综述。 Incidence rate of carcinoma of the esophagogastric junction (CEG) has obviously risen. However, the classification, etiopathogenisis and therapeutic principle of CEG are still in dispute because of complexity of anatomical location and structure of the cardia. At present, Siewert's classification of CEG,which divided CEG into three separate subtypes: Type Ⅰ,Type Ⅱ and Type Ⅲ,has come into popular use by many scholars. The important factors resuiting in CEG include gastroesophageal reflux disease, esophageal hiatal hernia, helicobacter pylori, dietary factors, living habit and drug. These factors lead to gene and chromosome abnormalities of epithelial cell, finally result in the transformation of normal human cells into tumor cells. However,the mechanisms are still under dispute or study. The article reviews the recent advances in this field.
出处 《现代肿瘤医学》 CAS 2010年第1期194-197,共4页 Journal of Modern Oncology
关键词 食管胃交界部肿瘤 胃癌 食管癌 carcinoma of esophagogastric iunction gastric carcinomas esophageal carcinomas
  • 相关文献

参考文献6

二级参考文献33

共引文献213

同被引文献21

  • 1Mehmet Fatih Can,Gokhan Yagci,Sadettin Cetiner.Sentinel lymph node biopsy for gastric cancer:Where do we stand?[J].World Journal of Gastrointestinal Surgery,2011,3(9):131-137. 被引量:4
  • 2王鲁平,虞积耀,丁华野.食管胃交界部位病变[J].临床与实验病理学杂志,2004,20(6):647-649. 被引量:6
  • 3王建红,何松,陈冬梅,谭清和,龚振夏,朱亚芳.Her-2/neu基因过表达与胃癌生物学行为的关系研究[J].临床肿瘤学杂志,2006,11(2):105-109. 被引量:4
  • 4Ilson DH. Esophageal cancer chemotherapy: recent advances[J]. Gastrointest Cancer Res,2008,2(2) : 85-92.
  • 5Novotny AR, Schuhmacher C, Busch R,et al. Predictinga U. S. -derived nomogram at a single high-volume center inEurope[J]. Ann Surg,2006,243(1):74-81.
  • 6Van Cutsem E, Kang Y, Chung HC, et al. Efficacy resultsfrom the ToGA trial; a phase DI study of trastuzumab addedto standard chemotherapy(CT) in first-line human epidermalgrowth factor receptor 2 ( HER2 )-positive advancedgastriccancer(GC)[J]. J Clin Oncol,2009,27(18 Suppl) :LBA4509.
  • 7Chung HC, Bang Y, Van Cutsem E,et al. (Q)-TWiSTanalysis of trastuzumab plus fluoropyrimidine/ cisplatin(T-XP/FP) versus XP/FP alone as first-line therapy foradvanced HER2-positive gastric cancer [J]. J Clin Oncol,2010,28(15 Suppl) :Abstr 4048.
  • 8Reichelt U? Duesedau P,Tsourlakis MCh, et al. Frequenthomogeneous HER-2 amplification in primary and metastaticadenocarcinoma of the esophagus [J]. Mod Pathol,2007, 20(1):120-129.
  • 9Dent R,Trudeau M,Pritchard KI,et al. Triple-negative breastcancer; clinical features and patterns of recurrence [J〕. ClinCancer Res,2007,13(15 Pt 1):4429-4434.
  • 10Varshney D, Zhou YY, Geller SA, et al. Determination ofHER-2 status and chromosome 17 polysomy in breastcarcinomas comparing HercepTest and PathVysion FISHassay [J], Am J Clin Pathol ?2004,121(1) : 70-77.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部